Biopharmaceutical company AbbVie (NYSE: ABBV) announced on Monday that it will present 17 abstracts at the 19th ECCO Congress, with data from its inflammatory bowel disease (IBD) portfolio. The event, held in Stockholm from 21-24 February 2024, will feature nine oral presentations and eight posters.
Key data presentations includes post-hoc analyses of the SEQUENCE trial comparing risankizumab (SKYRIZI versus ustekinumab for Crohn's disease (CD) outcomes. The COMMAND Phase 3 study showed risankizumab as a maintenance therapy in ulcerative colitis (UC), and U-ENDURE trial results exhibited long-term safety of upadacitinib (RINVOQ) in Crohn's disease (CD).
The research underscores AbbVie's commitment to advancing standards of care in IBD and understanding the gastroenterology community's needs.
Risankizumab is not approved for ulcerative colitis treatment.
SKYRIZI, an interleukin-23 (IL-23) inhibitor, selectively blocks IL-23 by binding to its p19 subunit. Approved by the FDA and EMA, SKYRIZI treats plaque psoriasis, psoriatic arthritis and Crohn's disease.
RINVOQ, a selective JAK inhibitor developed by AbbVie, is being studied in various immune-mediated inflammatory diseases, including Crohn's disease and ulcerative colitis.
With a robust clinical trial program, AbbVie is committed to cutting-edge research in inflammatory bowel diseases. The company aims to eliminate the burden of IBD and make a positive impact on patients' lives. AbbVie's mission is to discover and deliver innovative solutions across key therapeutic areas, including immunology, oncology, neuroscience, and eye care.
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma